Hims & Hers Health, Inc.(HIMS)Earnings, Financials & Key RatiosHims & Hers Health, Inc. (HIMS) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's shift to a debt-heavy capital structure, combined with a 2026Q1 net loss of $92.1 million and a compressed current ratio of 1.69, suggests significant fundamental instability.
Hims & Hers Health, Inc. (HIMS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Hims & Hers Health, Inc. (HIMS) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.40vs $0.03-1676.7% | $608Mvs $617M-1.4% |
| Q1 2026 | Feb 23, 2026 | $0.07vs $0.02+250.0% | $618Mvs $619M-0.2% |
| Q4 2025 | Nov 3, 2025 | $0.06vs $0.09-33.3% | $599Mvs $618M-3.1% |
| Q3 2025 | Aug 4, 2025 | $0.17vs $0.18-5.6% | $545Mvs $584M-6.7% |
Recent stock market news and headlines for Hims & Hers Health, Inc. (HIMS)
Hims & Hers Health continues to drive impressive growth through its subscription-based consumer wellness platform. Teladoc Health maintains a dominant market share with over 100 million global members and significant institutional partnerships.
The healthcare sector is one of the best-performing sectors in the S&P 500 over the past month, with a gain of around 6%. But while that rebound has been led by a handful of mega-cap Big Pharma companies, it has also been reflected in the performances of smaller firms.
The stock rebounded from below $14 after a regulatory shock and is now trading above $37 on a diversified growth narrative. Monthly weight-loss subscriber additions exceed one hundred thousand, transforming GLP-1 products into a powerful customer acquisition funnel. Peptides, AI healthcare systems, and international expansion create multi-layered optionality beyond traditional telehealth and pharmacy models.
The Amplify Online Retail ETF (IBUY) has rallied over the past month, signaling a robust appetite for online consumer discretionary spending despite persistent macroeconomic headwinds. Outsized gains in specialized healthcare retail and online travel names have driven performance for IBUY's underlying index.
Hims & Hers Health shares (HIMS) surged 9% on Wednesday after Canaccord Genuity raised its price target on the telehealth company, citing improving sales trends, momentum in its weight-loss business, and growing optimism around its peptide opportunity. Canaccord analyst Maria Ripps maintained a Buy rating on the stock while increasing her price target to $40 from $32, implying additional upside from current levels.
Key metrics vs top competitors for Hims & Hers Health, Inc. (HIMS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $36.17 | $7.94B | 70.92 | 59% | 5.47% | 25.23% | — | |
| $9.10 | $1.64B | -7.98 | -1.54% | -6.81% | -12.37% | — | |
| $22.74 | $4.25B | 23.20 | 13.05% | 30.4% | 19.36% | — | |
| $6.29 | $118.03M | 23.30 | 18.78% | 6.37% | 5.47% | — | |
| $237.59 | $166.46B | 170.93 | 35.82% | 12.31% | 3.49% | — | |
| $49.64 | $220.59B | 14.10 | 6.43% | 37.2% | 66.36% | — |
Hims & Hers Health, Inc. (HIMS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Hims & Hers Health, Inc. (HIMS) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 21, 2026·SEC
May 19, 2026·SEC
May 11, 2026·SEC
Feb 23, 2026·SEC
Get notified when HIMS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Hims & Hers Health, Inc. (HIMS) stock FAQ — growth, dividends, profitability & financials explained
Hims & Hers Health, Inc. (HIMS) reported $2.37B in revenue for fiscal year 2025. This represents a 2770% increase from $82.6M in 2019.
Hims & Hers Health, Inc. (HIMS) grew revenue by 59.0% over the past year. This is strong growth.
Hims & Hers Health, Inc. (HIMS) reported a net loss of $13.2M for fiscal year 2025.
Hims & Hers Health, Inc. (HIMS) has a return on equity (ROE) of 25.2%. This is excellent, indicating efficient use of shareholder capital.
Hims & Hers Health, Inc. (HIMS) generated $75.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
